TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01550315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calf Blood Flow in Reactive Hyperemia (CBF-RH)
Description: Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed

Intervention type: DEVICE
Group type: OTHER
Intervention: Calf Blood Flow in Reactive Hyperemia (CBF-RH)
Description: Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (\~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of Forearm-Mediated Dilation
Description: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Evaluation of Forearm-Mediated Dilation
Description: The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
Study: NCT01445002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM32
Description: Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
Study: NCT01836549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imetelstat sodium
Description: Given IV
Study: NCT01377038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phenotype assessment
Description: Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
Study: NCT04423887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Interferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Tibio-femoral Anterior Glide Tibio-femoral Posterior Glide Patellofemoral Joint Mobilization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
Study: NCT02308852

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Study: NCT04938557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated closed-loop insulin delivery (AiD)
Description: Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A standard insulin delivery system
Description: Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.
Study: NCT03892590

Intervention type: BIOLOGICAL
Intervention: Gut microbiota
Description: Status of microbiota
Study: NCT01166724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Tacrolimus to Sirolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: dosage per trough level
Study: NCT00965588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB 311
Description: Single liquid dose by intramuscular route at weeks 0, 4, 12.
Study: NCT03927664

Intervention type: OTHER
Intervention: Radiological assessment
Description: Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
Study: NCT00909116

Intervention type: PROCEDURE
Intervention: Stapled Transanal Rectal Resection with Contour Transtar
Description: Transanal Stapling procedure - Stapled Transanal Rectal Resection
Study: NCT04364607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Participants will receive 0.5 mg IM neostigmine
Study: NCT01396629

Intervention type: PROCEDURE
Intervention: cartridge
Description: IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
Study: NCT04364607

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Participants will receive IM NaCl 0.9% as a placebo
Study: NCT03303079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 or placebo
Description: TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Study: NCT02208453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSpace Implantation
Description: InSpace device Implantation
Study: NCT01095653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Study: NCT02962102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol
Description: Calcifediol 400mcg orally x 1, followed by 200mcg orally daily x 4
Study: NCT01095653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Study: NCT01174927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diacetylmorphine (DAM)
Description: The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02237859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit juice/placebo
Description: Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
Study: NCT01782859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Prednisone)
Study: NCT02680912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm needle acupuncture
Description: There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle acupuncture
Description: The point selection protocol will be exactly the same as the experimental group
Study: NCT03097874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: Family Based Treatment of adolescent Anorexia Nervosa

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment + Intensive Parental Coaching
Description: Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
Study: NCT02360956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil tablets
Description: Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive medication (per doctor suggestion)
Description: Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
Study: NCT00571987

Intervention type: DEVICE
Group type: OTHER
Intervention: AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)
Description: Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
Study: NCT01095653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks
Study: NCT00138476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk Virus
Description: Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk Virus
Description: Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk Virus
Description: Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk Virus
Description: Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
Study: NCT02962102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol 4mcg orally daily x 5

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo (medium chain triglyceride oil) orally daily x 5
Study: NCT01095653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Placebo
Description: Tablets, Oral, 0 mg, Once daily, 24 weeks
Study: NCT02978105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-conditioning techniques
Description: Self-hypnosis to increase self-control before meals and every food compulsion episode
Study: NCT00138476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk Virus
Description: Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses \[reverse transcription polymerase chain reaction (RT-PCR) Units\] 4800, 48, 4.8, 0.48.
Study: NCT00067366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral treatment
Description: Cognitive-Behavioral skills training for chronic pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention and lifestyle counseling
Description: Attention and lifestyle counseling added to Standard Care
Study: NCT02069743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePAL Mobile Application
Description: A mobile application designed to help cancer patients better self-manage cancer pain.
Study: NCT01626560

Intervention type: DRUG
Group type: OTHER
Intervention: Daptomycin
Description: daptomycin 4-6mg/kg qd 10 - 14 days

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: Vancomycin 1g q12h 10 - 14 days
Study: NCT02282670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stillen tab.
Study: NCT03535870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
Description: Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo dry powder administered via the LOMI inhaler device
Study: NCT01111149

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill created and masked by the pharmacy to be used as a control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion HCl
Description: in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
Study: NCT03020680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
Study: NCT00938379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% deet insect repellent
Description: skin-applied repellent lotion
Study: NCT02978105

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care (diet, exercise and behavioral therapy)
Description: dietary recommendations, exercise recommendations, and behavioral recommendations
Study: NCT00399685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen LO
Description: Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
Study: NCT00938379

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Identical base formulation of lotion but without any deet active
Study: NCT03032666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/velpatasvir
Description: treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
Study: NCT03835611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game based treadmill Platform
Description: The protocol for the intervention group will be:~* Warm up exercised consisting of rhythmical large movements (10minutes)~* Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~* DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: * Warm-up exercise consisting of rhythmical large movements (10 minutes).~* Core standing balance exercises on a sponge surface (10 minutes).~* Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~* Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes).
Study: NCT03296657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride
Description: subjects will brush with paste twice daily for 2 weeks
Study: NCT00399685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen
Description: Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Cyclen + Efavirenz
Description: Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
Study: NCT02978105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care (diet, exercise and behavioral therapy)
Description: dietary recommendations, exercise recommendations, and behavioral recommendations
Study: NCT02674282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Description: ACL reconstruction with hamstrings autograft.